Skip to main content

Table 3 Baseline and intraoperative characteristics of patients

From: Cardiac implantable electronic device surgery with interruption of warfarin forgoing post-operative bridging therapy in patients with moderate or high thromboembolic risks

  All patients Mechanical valve No mechanical valve
N = 411 N = 257 N = 154
CIED procedure - no. (%)
 New implant
  Pacemaker
   Single or dual chamber 131 31.9% 81 31.5% 50 32.5%
   Cardiac resynchronization therapy 14 3.4% 9 3.5% 5 3.3%
  Implantable cardioverter-defibrillator
   Single or dual chamber 21 5.1% 6 2.3% 15 9.7%
   Cardiac resynchronization therapy 27 6.6% 9 3.5% 18 11.7%
  Device replacement or revision
   Pulse-generator change only 191 46.5% 129 50.2% 6 40.3%
   Pulse-generator change with additional procedure 27 6.6% 23 9.0% 4 2.6%
INR on day of surgery - mean ± S.D. 1.44 ± 0.22 1.44 ± 0.21 1.43 ± 0.24
 Warfarin resumption after surgery -days
  Mean ± S.D. 0.46 ± 1.01 0.23 ± 0.51 0.84 ± 1.45
  Median, IQR 0 0–1 0 0–0 0 0–1
 Anti-coagulation interruption period - days
  Mean ± S.D. 4.04 ± 2.04 3.91 ± 1.71 4.27 ± 2.47
  Median (IQR) 3 3–5 3 3–5 4 3–5
  1. Abbreviations: CIED cardiac implantable electronic device, S.D. standard deviation, IQR interquartile range